Provided by Tiger Trade Technology Pte. Ltd.

LAVA Therapeutics N.V.

1.74
0.0000
Volume:- -
Turnover:- -
Market Cap:45.77M
PE:-2.02
High:1.74
Open:1.74
Low:1.74
Close:1.74
52wk High:2.00
52wk Low:0.8502
Shares:26.31M
Float Shares:10.22M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8620
EPS(LYR):-0.9359
ROE:-101.51%
ROA:-19.92%
PB:3.61
PE(LYR):-1.86

Loading ...

Company Profile

Company Name:
LAVA Therapeutics N.V.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.